| MHS | major histocompatibility system; malignant hyperthermia in swine; malignant hyperthermia syndrome; m... |
|---|---|
| MIMS | medical information management system; medical inventory management system |
| PDS | pain-dysfunction syndrome; paroxysmal depolarizing shift; patient data system; Patient-Doctor Societ... |
| PPS | Personal Preference Scale; physician, patient and society [course]; polyvalent pneumococcal polysacc... |
| RAS | rapid atrial stimulation; recurrent aphthous stomatitis; reflex activating stimulus; reliability, av... |
| haematologic, gastrointestinal, and renal agents | A collective grouping for agents that act on the haematopoietic, gastrointestinal, and renal systems. (12 Dec 1998) |
|---|---|
| cryoprotective agents | Substances capable of protecting against injury due to freezing, as glycerol protects frozen red blood cells. (12 Dec 1998) |
| hepatitis agents, gb | Proposed members of the family flaviviridae. Gbv-b causes hepatitis in tamarins and possibly humans, and is the putative aetiological agent of a non-(a-e) hepatitis, gb hepatitis. (12 Dec 1998) |
| protective agents | Synthetic or natural substances which are given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. (12 Dec 1998) |
| histamine agents | Drugs used for their actions on histaminergic systems. Included are drugs that act at histamine receptors, affect the life cycle of histamine, or affect the state of histaminergic cells. (12 Dec 1998) |
| serotonin agents | Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons. (12 Dec 1998) |
| hypoglycaemic agents | Agents which lower the blood glucose level. (12 Dec 1998) |
| spermatocidal agents | Chemical substances that are destructive to spermatozoa used as topically administered vaginal contraceptives. (12 Dec 1998) |
| spermatogenesis-blocking agents | Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa. (12 Dec 1998) |
| sperm immobilizing agents | Chemical substances with sperm immobilizing activity used as topically administered vaginal contraceptives. (12 Dec 1998) |
| neuromuscular agents | Drugs used for their actions on skeletal muscle. Included are agents that act directly on skeletal muscle, those that alter neuromuscular transmission (neuromuscular blocking agents), and drugs that act centrally as skeletal muscle relaxants (muscle relaxants, central). Drugs used in the treatment of movement disorders are anti-dyskinesia agents. (12 Dec 1998) |
| neuromuscular blocking agents | Drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. They can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarising agents) or noncompetitive, depolarising agents (neuromuscular depolarising agents). Both prevent acetylcholine from triggering the muscle contraction and they are used as anaesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc. (12 Dec 1998) |
| neuromuscular depolarising agents | Drugs that interrupt transmission at the skeletal neuromuscular junction by causing sustained depolarisation of the motor end plate. These agents are primarily used as adjuvants in surgical anaesthesia to cause skeletal muscle relaxation. (12 Dec 1998) |
| neuromuscular nondepolarising agents | Drugs that interrupt transmission at the skeletal neuromuscular junction without causing depolarisation of the motor end plate. They prevent acetylcholine from triggering muscle contraction and are used as muscle relaxants during electroshock treatments, in convulsive states, and as anaesthesia adjuvants. (12 Dec 1998) |
| neuroprotective agents | Drugs intended to prevent damage to the brain or spinal cord from ischemia, stroke, convulsions, or trauma. Some must be administered before the event, but others may be effective for some time after. They act by a variety of mechanisms, but often directly or indirectly minimise the damage produced by endogenous excitatory amino acids. (12 Dec 1998) |